Sumatriptan Succinate Tablet, Film Coated
Product Images NDC 71205-251

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 71205-251). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of sumatriptan succinate, showing its indole-based molecular framework with a sulfonamide side chain and succinate moiety.*
FDA Label Image

71205-251-09 (Sumatriptan Carton 50mg)

71205-251-09 (Sumatriptan Carton 50mg)
Label for Sumatriptan Succinate 50 mg film-coated tablets by Proficient Rx LP. It indicates that each tablet contains 50 mg of sumatriptan succinate, and the tablets are white, triangular-shaped, with an 'S' debossed on one side and '50' on the other. The label includes the NDC 71205-251-09, packaging quantity (#09 tablets), and manufacturing details from Sun Pharmaceutical Industries Ltd., India.*
FDA Label Image

Sumatriptan-figure-1 (Sumatriptan Figure 1)

Sumatriptan-figure-1 (Sumatriptan Figure 1)
A Kaplan-Meier plot illustrating the estimated probability of achieving initial headache response within 4 hours following oral sumatriptan treatment. The graph compares placebo to three sumatriptan doses: 25 mg, 50 mg, and 100 mg, showing increasing probability of response over time up to 240 minutes from initial dose, with higher doses generally yielding higher response rates.*
FDA Label Image

Sumatriptan-figure-2 (Sumatriptan Figure 2)

Sumatriptan-figure-2 (Sumatriptan Figure 2)
A Kaplan-Meier plot showing the estimated probability over 24 hours of patients taking a second dose of sumatriptan succinate tablets or other medication for migraine after the initial dose. The plot compares placebo and sumatriptan doses of 25 mg, 50 mg, and 100 mg, with probability on the y-axis and time in hours from the initial dose on the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.